Home Featured Page 201

Featured

Latest

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

Weekly Psychedelic Policy Briefing: August 23, 2026

Field Notes #4: Resilient Refiles, Definium’s Readout, HRSA’s RFI Responses, and J&J’s Neuroplastogen Bet

Red Light Holland Reports Fiscal Third Quarter Results

Field Trip Health and Cerebral Partner to Provide End-to-End Mental Health...

PT297 – Laura Mae Northrup, LMFT – Radical Healership in a...

Psychedelic Bulletin: Following the Money – How Much do Psychedelics Companies...

HAVN Life Secures Purchase Order for Controlled Substance Sale to Revive...

Lobe Sciences Ltd. Strengthens Its Balance Sheet

Entheon Biomedical Announces EBIQ-101 First-Patient Dose

COMPASS Pathways announces financial results for the fourth quarter and full...

MindMed Converts Multiple Voting Shares to Subordinate Voting Shares

PharmaDrug Receives Positive Results for DMT-Analogue Program to Treat Glaucoma

EDITOR PICKS

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic...

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

Who Gets to Heal?

Weekly Psychedelic Policy Briefing: August 23, 2026

Field Notes #4: Resilient Refiles, Definium’s Readout, HRSA’s RFI Responses, and J&J’s Neuroplastogen Bet

Red Light Holland Reports Fiscal Third Quarter Results

Field Trip Health and Cerebral Partner to Provide End-to-End Mental Health...

PT297 – Laura Mae Northrup, LMFT – Radical Healership in a...

Psychedelic Bulletin: Following the Money – How Much do Psychedelics Companies...

HAVN Life Secures Purchase Order for Controlled Substance Sale to Revive...

Lobe Sciences Ltd. Strengthens Its Balance Sheet

Entheon Biomedical Announces EBIQ-101 First-Patient Dose

COMPASS Pathways announces financial results for the fourth quarter and full...

MindMed Converts Multiple Voting Shares to Subordinate Voting Shares

PharmaDrug Receives Positive Results for DMT-Analogue Program to Treat Glaucoma

EDITOR PICKS

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic...

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

Who Gets to Heal?

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY